|
5.12 Immunothérapies
|
|
|
|
|
5.6.4 ESMO - Poumon
|
|
|
|
|
|
|
5.9.3 AACR - mélanome
|
|
|
|
|
|
|
5.9.5 AACR - T-cell immunothérapies
|
|
|
|
|
AACR – Mage-A3 double-whammy hits Kite [EP Vantage]
|
|
|
|
|
|
Given
its relevance to Kite Pharma, the NCI’s data on an engineered T-cell
receptor against Mage-A3 was a keenly awaited AACR presentation, but
when it went live on Sunday researchers could boast of no new responses
versus what had been presented last November.
|
|
|
|
|
|
|
5.9.7 AACR - divers
|
|
|
|
|
|
|
|
|
6. Lutte contre les cancers
|
|
|
|
Get Involved [National Cancer Institute]
|
|
|
|
|
|
Visit
our online platform, Cancer Research Ideas, to submit your best
scientific ideas for bringing about a decade’s worth of advances in 5
years, making more therapies available to more patients, and spurring
progress in cancer prevention, treatment, and care.
|
|
|
|
|
|
|
6.10 Politiques
|
|
|
|
6.11 Patients
|
|
|
|
6.4 Médico-éco
|
|
|
|
6.6 Publications
|
|
|